Florida

Start Pallas's online intake — it takes about 5 minutes and covers your health history, goals, and current medications. A provider authorized to treat Florida patients — either Florida-licensed or a registered out-of-state telehealth provider under Florida Statutes Chapter 456 — reviews it, and because Florida allows asynchronous-first care for non-controlled medications like GLP-1s, that review can happen by secure message without a scheduled video call, unless your history calls for one. If a GLP-1 is clinically appropriate, your clinician prescribes it, and a US-licensed pharmacy ships your medication to any Florida address within a few business days.

The process is the same as for semaglutide — complete Pallas's online intake, and a provider authorized to treat Florida patients reviews it, asynchronously in most cases, since Florida allows telehealth providers to establish care and prescribe without a live video visit when the standard of care is met. If appropriate, your clinician can prescribe compounded tirzepatide, prepared per-patient by a US-licensed §503A compounding pharmacy based on a documented clinical rationale, or an FDA-approved brand-name option like Zepbound^® or Mounjaro^®, through the same intake. These are distinct products with different regulatory status; your clinician will explain which fits you.

Yes — compounded semaglutide is available to eligible Florida residents through licensed telehealth. It is prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a provider authorized to treat Florida patients must prescribe it based on a documented, patient-specific clinical rationale. Pallas serves Florida with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes — through either of two tracks. Most Florida nurse practitioners prescribe under a written protocol with a supervising physician, and NPs who hold Florida's autonomous practice registration can prescribe independently within primary care. Florida law explicitly allows the provider-patient relationship to be established by telehealth for non-controlled medications like semaglutide and tirzepatide. Every Pallas clinician who treats Florida patients holds an active Florida license.

Several licensed telehealth platforms serve Florida residents seeking compounded semaglutide. Before choosing one, verify that its clinicians are authorized to treat Florida patients, that it works with US-licensed §503A compounding pharmacies, and that it holds LegitScript Healthcare Merchant Certification — you can check any platform's certification status in LegitScript's public database. Pallas serves Florida residents and is LegitScript Healthcare Merchant Certified.

No — Florida is asynchronous-first for non-controlled medications like GLP-1s. A provider authorized to treat Florida patients can review your secure-message intake and, if appropriate, prescribe semaglutide without a scheduled video call, as long as the standard of care is met. Your provider may request a brief video visit or additional information only if your history calls for it.

Most Florida patients complete Pallas's online intake in about five minutes, and a provider authorized to treat Florida patients typically reviews it within one to two business days, since Florida allows this review to happen asynchronously by secure message rather than a scheduled video call. Once your clinician prescribes, a US-licensed pharmacy fills and ships your medication, typically within 2–3 business days of the pharmacy filling the prescription. The most common delays are an incomplete intake or an issue verifying your ID or photos, so responding quickly to any follow-up message from your care team keeps things on track. There's no guaranteed delivery date, since timing depends on your clinician's review and the pharmacy's fill queue.

Yes — access to Pallas's telehealth intake and clinician review is the same no matter where in Florida you live, from Jacksonville, Miami, Tampa, Orlando, and St. Petersburg to smaller Panhandle communities and rural counties without a nearby obesity medicine specialist. A licensed partner pharmacy ships to every ZIP code in Florida, including South Florida's Miami-Dade, Broward, and Palm Beach communities and the Panhandle stretching to Pensacola. Your intake, clinician review, and pricing are identical no matter which part of the state you're in.

Several licensed telehealth providers prescribe tirzepatide to Florida residents. Before choosing one, verify that its clinicians are authorized to treat Florida patients — either Florida-licensed or registered as an out-of-state telehealth provider under Florida Statutes Chapter 456 — that it works with US-licensed §503A compounding pharmacies for the compounded option, and that it holds LegitScript Healthcare Merchant Certification, which you can check in LegitScript's public database. Pallas serves Florida residents, is LegitScript Healthcare Merchant Certified, and offers both compounded tirzepatide and the FDA-approved options Zepbound^® and Mounjaro^® through the same intake.

Florida Medicaid covers GLP-1s for type 2 diabetes and, in limited cases, for weight management with prior authorization. Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid coverage does not apply to our prescriptions.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your Florida address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Miami, Tampa, or a rural Florida ZIP code.

In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Eligibility is always decided by a clinician authorized to treat Florida patients after reviewing your full intake, never by an automated quiz — your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need — legal in Florida when prescribed by a provider authorized to treat Florida patients and dispensed by a licensed compounding pharmacy. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Florida provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now, how you have tolerated it, and list every other prescription, over-the-counter medication, and supplement you currently take, so your provider can review for interactions before prescribing — common medications like metformin, blood pressure medication, and hormonal birth control don't automatically rule you out. Your Florida provider reviews that full history and, if appropriate, continues you at a comparable dose or adjusts your titration plan, and will tell you directly if a GLP-1 isn't appropriate alongside something you're taking. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician authorized to treat Florida patients — either Florida-licensed or a registered out-of-state telehealth provider under Florida Board of Medicine oversight — reviews it asynchronously in most cases, with no live video required, and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Florida address, usually within 2–3 business days.

After your Florida provider approves your prescription, your first shipment ships to your address — most Florida patients receive it within 2–3 business days of the pharmacy filling the prescription, with Miami, Tampa, Orlando, and Jacksonville metros typically fastest and rural ZIP codes taking an extra day — and most patients start on a low dose that's titrated up gradually to help minimize side effects like nausea. Your care team checks in by secure message during the first few weeks to see how you're tolerating the medication, and your provider can adjust your dose directly in the app if needed — a separate visit usually isn't required. After that, Pallas care is ongoing, not a one-time script — your plan renews on a regular cadence so your medication arrives before you run out, and you can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Florida address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any Florida address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® and Zepbound^® for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to Florida patients cash-pay from $1069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in Florida during intake.

Coverage of GLP-1 medications for weight loss through Medicaid is limited. Florida Medicaid covers GLP-1s for type 2 diabetes and, in limited cases, weight management with prior authorization. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Medicaid or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

Losing coverage doesn't have to interrupt treatment. Pallas is cash-pay — no insurance required — with two paths in Florida: staying on FDA-approved brand-name Wegovy^® or Zepbound^® at flat cash-pay pricing from $1069/mo, or, when a clinician licensed in Florida determines it is clinically appropriate for you, a compounded semaglutide or tirzepatide plan at a lower price point (current terms are in the cost questions on this page). During intake, tell your clinician what you are taking now and your current dose — they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in Florida weighs your history, goals, and budget to recommend a starting point.